PharmaCyte Biotech Inc (PMCB) Q3 2025: Pmcb

Executive Summary

PharmaCyte Biotech (PMCB) reported QQ3 2025 with no revenue and a material net loss, underscoring the company’s continued status as a development-stage biotechnology firm. The quarter shows an operating loss of $0.960 million and a net loss of $3.045 million, driven largely by non-cash and other charges alongside ongoing G&A spend. While operating metrics reflect a modest quarterly deterioration in profitability on an absolute basis, the company maintains ample liquidity (cash and equivalents of $16.38 million and a current ratio of 14.20) which provides a near-term runway to advance its pipeline and seek transformative partnerships or milestone-based funding. The company’s balance sheet shows a substantial accumulated deficit but a relatively strong equity base and minimal near-term debt, suggesting a financing-dependent path to future value creation typical of early-stage biotech.

Key Performance Indicators

Operating Income

-960.25K

QoQ: 13.18% | YoY:48.62%

Net Income

-3.05M

QoQ: -107.23% | YoY:-391.18%

EPS

-0.44

QoQ: -12.82% | YoY:32.31%

Revenue Trend

Margin Analysis

Key Insights

Revenue: null (no reported revenue in QQ3 2025).
Operating Income: -$0.960 million; YoY: 48.62% growth; QoQ: 13.18% growth.
Net Income: -$3.045 million; YoY: -391.18%; QoQ: -107.23%.
EPS: -$0.44; YoY: 32.31%; QoQ: -12.82%.
Cash flow from operations: -$0.509 million; Free cash flow: -$0.509 million.

Financial Highlights

Overview of the QQ3 2025 metrics, with YoY and QoQ context where available:
- Revenue: null (no reported revenue in QQ3 2025).
- Operating Income: -$0.960 million; YoY: 48.62% growth; QoQ: 13.18% growth.
- Net Income: -$3.045 million; YoY: -391.18%; QoQ: -107.23%.
- EPS: -$0.44; YoY: 32.31%; QoQ: -12.82%.
- Cash flow from operations: -$0.509 million; Free cash flow: -$0.509 million.
- End-of-period cash and equivalents: $16.38 million; Current ratio: 14.20; Cash conversion dynamics indicate a liquidity buffer in a no-revenue environment.
- Shares outstanding (weighted average): 6.96 million; EPS diluted: -$0.44.

Income Statement

Metric	Value	YoY Change	QoQ Change
Operating Income	-960.25K	48.62%	13.18%
Net Income	-3.05M	-391.18%	-107.23%
EPS	-0.44	32.31%	-12.82%

Key Financial Ratios

currentRatio

14.2

returnOnAssets

-6.95%

returnOnEquity

-7.57%

operatingCashFlowPerShare

$-0.07

freeCashFlowPerShare

$-0.07

priceToBookRatio

0.28

priceEarningsRatio

-0.91

Net Income vs. Revenue

Expense Breakdown

Competitive Position

Company	Gross Margin	Operating Margin	Return on Equity	P/E Ratio
PMCB Focus	0.00%	0.00%	-7.57%	-91.40%
XBIT	0.00%	0.00%	-2.61%	-11.74%
PMVP	0.00%	0.00%	-9.71%	-99.90%
LENZ	0.00%	0.00%	-4.74%	-15.79%
OVID	1.00%	-76.45%	-18.40%	-1.50%

Period	EPS ($)	YoY Growth	Report
Q1 2026	-1.23	+0.0%	View
Q3 2025	-0.44	+0.0%	View
Q2 2025	-0.39	+0.0%	View
Q1 2025	1.90	+0.0%	View
Q4 2024	0.17	+0.0%	View

PharmaCyte Biotech Inc (PMCB) Q3 2025 Earnings Report

Earnings Highlights

PharmaCyte Biotech Inc (PMCB) QQ3 2025 Results: Liquidity Supports Near-Term Operations Amid Ongoing Net Loss in a High-Risk Biotech Landscape

Executive Summary

Key Performance Indicators

Operating Income

Net Income

EPS

Revenue Trend

Margin Analysis

Key Insights

Financial Highlights

Income Statement

Key Financial Ratios

Net Income vs. Revenue

Expense Breakdown

Management Commentary

Forward Guidance

Competitive Position

Gross Profit Margin

Operating Profit Margin

Return on Equity

P/E Ratio Comparison

Investment Outlook

Key Investment Factors

Growth Potential

Profitability Risk

Financial Position

SWOT Analysis

Strengths

Weaknesses

Opportunities

Threats

Historical Earnings Comparison

PharmaCyte Biotech Inc (PMCB) Q3 2025 Earnings Report

Earnings Highlights

Executive Summary

Key Performance Indicators

Operating Income

Net Income

EPS

Revenue Trend

Margin Analysis

Key Insights

Financial Highlights

Income Statement

Key Financial Ratios

Net Income vs. Revenue

Expense Breakdown

Management Commentary

Forward Guidance

Competitive Position

Gross Profit Margin

Operating Profit Margin

Return on Equity

P/E Ratio Comparison

Investment Outlook

Key Investment Factors

Growth Potential

Profitability Risk

Financial Position

SWOT Analysis

Strengths

Weaknesses

Opportunities

Threats

Historical Earnings Comparison

More PMCB Quarterly Reports

PMCB

PMCB

PMCB

PMCB

Q3 2025 Reports in Healthcare Sector

Related Financial Data

Sector Analysis: Healthcare

PMCB Full Profile

PMCB Financial Statements

Earnings Calendar